Update to Interim guidance for preexposure prophylaxis (PrEP) for the prevention of HIV infection : PrEP for injecting drug users

Details

• Journal Article:
  Morbidity and Mortality Weekly Report (MMWR)
• Personal Author:
  Smith, Dawn K. ; Martin, Michael ; Lansky, Amy ; Mermin, Jonathan ; Choopanya, Kachit
• Corporate Authors:
  Centers for Disease Control and Prevention (U.S.) ; Bangkok Tenofovir Study Group.
• Description:
  On June 12, 2013, the Thailand Ministry of Health and CDC published results from a randomized controlled trial of a daily oral dose of 300 mg of tenofovir disoproxil fumarate (TDF) that showed efficacy in reducing the acquisition of human immunodeficiency virus (HIV) infection among injecting drug users (IDUs) (1). Based on these findings, CDC recommends that preexposure prophylaxis (PrEP) be considered as one of several prevention options for persons at very high risk for HIV acquisition through the injection of illicit drugs. ; PMID: 23760186
• Subjects:
  • Adenine/analogs & derivatives
  • Adenine/therapeutic use
  • Anti-HIV Agents/therapeutic use
  • Deoxycytidine/analogs & derivatives
  • Deoxycytidine/therapeutic use
  • Female
  • HIV Infections/epidemiology
  • HIV Infections/prevention & control
  • Heterosexuality
  • Homosexuality, Male
  More +
• Source:
  MMWR. Morbidity and mortality weekly report. 2013 Jun 14; 62(23):463-5
• Series:
  Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
• ISSN:
  0149-2195 (print) ; 1545-861X (digital)
• Document Type:
  Journal Article
• Corporate as Subject:
  Centers for Disease Control and Prevention (U.S.) ; Centers for Disease Control and Prevention (U.S.)
• Genre:
  Practice Guideline
• Place as Subject:
  United States
• Pages in Document:
  3 pdf pages
• Volume:
  62
• Issue:
  23
• Download URL:
  https://stacks.cdc.gov/view/cdc/23107/cdc_23107_DS1.pdf
• File Type:
  [PDF - 72.62 KB]
• Collection(s):
  Morbidity and Mortality Weekly Report (MMWR) ; Guidelines and Recommendations
• Main Document Checksum:
  urn:sha-512:ee25e2f89f6113e6637b0741f0c4b378b67a0b47c00b76977b5cd0cba27ce858a58d238d4bf4566683f0431be52a686e4e23bd60f11582ae486a4f14652517b0